<DOC>
	<DOCNO>NCT00972127</DOCNO>
	<brief_summary>Primary : - To assess influence acidified urinary pH renal excretion Neramexane Secondary : - To assess influence acidified urinary pH renal excretion N-OH Neramexane - To assess steady state plasma pharmacokinetics ( PK ) Neramexane N-OH Neramexane physiological condition condition urine acidification - To assess safety tolerability repeat dose treatment Neramexane physiological condition condition urine acidification</brief_summary>
	<brief_title>Changes Renal Excretion Neramexane Acidification Urinary pH Study With Without Application Urinary pH Acidification Regimen</brief_title>
	<detailed_description />
	<criteria>Healthy adult subject ethnic origin , able read , write fully understand German language Aged 18 45 year BMI 1828 kg/m2 body weight 5090 kg Willing able provide write informed consent inform requirement restriction study Female subject childbearing potential must agree use effective method birth control sexual abstinence , vasectomise partner , non hormonal IUDs double contraception method ( e.g. , condom spermicide cream ) History clinically relevant allergy know hypersensitivity Neramexane/Memantine/Amantadine derivatives History clinically relevant allergy know hypersensitivity Ammonium Chloride Exposure another investigational agent within last two month Day 1 Period 1 History clinically relevant allergy know hypersensitivity inactive ingredient use investigational product tool substance Lactating pregnant female female planning become pregnant study conduct within 2 month end study . Male plan beget child study conduct within 2 month end study Any contraindication indicate topically valid SPC ExtinÂ®N : acidosis , gastritis , gastrointestinal ulcer , hepatic renal insufficiency , hypokalemia Lack suitability trial Any evidence significant cardiovascular , pulmonary , renal , hepatic , gastrointestinal , endocrinological , metabolic ( acidosis ) , psychiatric disease screen History malignancy Any clinically relevant deviation clinical laboratory assessment Clinically relevant abnormality 12lead ECG discretion investigator Merz scientific expert might affect study objective Systolic blood pressure &lt; 95 mmHg &gt; 150 mmHg diastolic blood pressure &lt; 50 mmHg &gt; 90 mmHg supine position Pulse rate &lt; 45 &gt; 100 beat per minute Clinically relevant chronic acute infection Acute chronic disease , especially psychiatric neurologic disorder Current evidence hypokalemia ( = low limit laboratory normal range plus 0.3 mmol/l safety margin ) History alcohol drug dependence within last 2 year Alcohol consumption average 40 g male 20 g female subject daily within last year Regular caffeine consumption average 1 L coffee and/or tea daily 1 L caffeinecontaining lemonade per day within last year Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence pharmacokinetics investigational medicinal product ( e.g . acute inflammation , gastrointestinal disease , cholecystectomy , resection small large intestine , etc . ) Use prescribed medication four week prior first administration IMP . Regular use overthecounter [ OTC ] drug 4 week prior first administration IMP Occasional use OTC drug ( except paracetamol , maximum 1 g/day ) within 2 week prior first administration IMP Stable intake thyroid hormone substitution allow . Use food , food supplement medication know induce inhibit CYP3A4 cytochrome P450 enzymes within two week precede start study ( Day 1 ) , e.g . grapefruit , St. John 's wort Special diet , e.g . vegetarian Female subject employ form hormonal contraception within 2 month prior Day 1 ( e.g . oral contraceptive , hormone release intrauterine contraceptive device [ IUDs ] , etc . ) Consume xanthine derivates ( include caffeine ) within two day prior Day 1 Smoker user snuff , nicotine replacement chew tobacco Previous enrolment clinical phase current study Positive result serology test Blood donation 450 mL within 60 day prior Day 1 Positive pregnancy test , female Positive drug screen alcohol test Administrative reason Lack willingness inability cooperate adequately Employee direct relative employee CRO Merz Pharmaceuticals GmbH Lack ability willingness give inform consent Vulnerable subject ( e.g . person keep detention ) Anticipated nonavailability study visits/procedures Inability follow study procedure investigator instruction adequately</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>